Please assess the completion status of the following clinical trial:

Trial Title: Anti-EGFR Therapy Plus IMRT Concurrent Chemoradiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed locally advanced NPC;~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;~* Normal complete blood count;~* Normal hepatic function;~* Normal renal function (creatinine ≤ 1.5 times the upper limit of normal).~Exclusion Criteria:~* Previous radiotherapy;~* A history of any other type of malignancy;~* Pregnancy or lactation;~* Allergy to anti-EGFR monoclonal antibody;~* Obvious disfunction of liver, renal, cardiac or lung function;~* Un controlled infection;~* Systemic metastasis or distant metastasis;~* Patients with severe gastrointestinal diseases;~* Patients with mental disorders affecting patient participation in trial judgement.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Anti-EGFR arm (Type: EXPERIMENTAL): In the induction chemotherapy phase, TP regimen (Docetaxel 75mg/m2, D1 + DDP 25mg/m2, D1-3, repeat every 3 weeks) or GP regimen (Gemcitabine 1.0g/m2, D1, 8 + DDP 25mg/m2 , D1-3, repeat every 3 weeks) will be used. Cetuximab 400mg/m2 will be used one week before radiotherapy and 250mg/m2/week during IMRT, or nimotuzumab 200mg/week; meanwhile, cisplatin 80mg/m2 will be used every 3 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).